WASHINGTON — A management shuffle at the Food and Drug Administration Monday moved two officials into high-ranking positions, giving them more authority over the agency’s strategy.
Theresa Mullin is moving up from being the director of the office of strategic programs at the Center for Drug Evaluation and Research — starting Monday, she’s working directly in the office of the CDER director, Janet Woodcock, as the associate director for strategic initiatives, according to an email that Woodcock sent to her staff.
Meanwhile, Keagan Lenihan, a former political appointee at the Department of Health and Human Services and an ally of former HHS Secretary Tom Price, was hired directly into the FDA commissioner’s office, Politico reported. Lenihan will take on the role of associate commissioner for strategic initiatives.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.